Entrada Therapeutics (TRDA) Scheduled to Post Earnings on Friday

Entrada Therapeutics (NASDAQ:TRDA) is scheduled to be posting its quarterly earnings results on Friday, March 8th.

Entrada Therapeutics Trading Up 1.5 %

TRDA traded up $0.19 during trading on Thursday, reaching $12.58. 69,769 shares of the company’s stock were exchanged, compared to its average volume of 79,795. Entrada Therapeutics has a one year low of $10.11 and a one year high of $18.44. The stock has a market capitalization of $419.79 million, a PE ratio of -16.55 and a beta of -0.52. The firm has a fifty day moving average price of $14.57 and a two-hundred day moving average price of $14.80.

Insider Activity

In related news, CFO Kory James Wentworth sold 10,206 shares of the business’s stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $15.69, for a total transaction of $160,132.14. Following the transaction, the chief financial officer now owns 49,571 shares in the company, valued at approximately $777,768.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 13,300 shares of company stock valued at $207,689. 7.58% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its position in shares of Entrada Therapeutics by 41.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,064 shares of the company’s stock valued at $273,000 after acquiring an additional 5,260 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Entrada Therapeutics by 0.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,009,673 shares of the company’s stock valued at $45,416,000 after acquiring an additional 9,636 shares during the period. Barclays PLC lifted its position in shares of Entrada Therapeutics by 434.9% during the 4th quarter. Barclays PLC now owns 31,730 shares of the company’s stock valued at $479,000 after acquiring an additional 25,798 shares during the period. Vanguard Group Inc. lifted its position in shares of Entrada Therapeutics by 4.4% during the 4th quarter. Vanguard Group Inc. now owns 1,065,166 shares of the company’s stock valued at $16,073,000 after acquiring an additional 44,849 shares during the period. Finally, Nuveen Asset Management LLC lifted its position in shares of Entrada Therapeutics by 9.7% during the 4th quarter. Nuveen Asset Management LLC now owns 80,510 shares of the company’s stock valued at $1,215,000 after acquiring an additional 7,148 shares during the period. Institutional investors and hedge funds own 77.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. HC Wainwright reduced their price objective on shares of Entrada Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, November 27th. Oppenheimer assumed coverage on shares of Entrada Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $22.00 price objective on the stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1.